{
    "id": 18258,
    "fullName": "AR negative",
    "impact": "unknown",
    "proteinEffect": "loss of function",
    "geneVariantDescriptions": [
        {
            "description": "AR negative indicates a lack of the AR gene, mRNA, and/or protein.",
            "references": [
                {
                    "id": 275,
                    "pubMedId": null,
                    "title": "External Reference Not Available (N/A)",
                    "url": "https://ckb.jax.org/about/glossaryOfTerms"
                }
            ]
        }
    ],
    "type": "non-specific",
    "gene": {
        "id": 367,
        "geneSymbol": "AR",
        "terms": [
            "AR",
            "AIS",
            "AR8",
            "DHTR",
            "HUMARA",
            "HYSP1",
            "KD",
            "NR3C4",
            "SBMA",
            "SMAX1",
            "TFM"
        ]
    },
    "variant": "negative",
    "createDate": "02/17/2016",
    "updateDate": "10/08/2019",
    "referenceTranscriptCoordinates": null,
    "partnerGenes": [
        
    ],
    "evidence": [
        {
            "id": 14234,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, PCM-075 sensitized AR-negative breast cancer cells to Zytiga (abiraterone) in culture (J Clin Oncol 36, 2018 (suppl 6S; abstr 369)).",
            "molecularProfile": {
                "id": 18586,
                "profileName": "AR negative"
            },
            "therapy": {
                "id": 7084,
                "therapyName": "Abiraterone + PCM-075",
                "synonyms": null
            },
            "indication": {
                "id": 1612,
                "name": "breast cancer",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 11559,
                    "pubMedId": null,
                    "title": "Combination of selective polo-like kinase 1 (PLK1) inhibitor PCM-075 with abiraterone in prostate cancer and non-androgen-driven cancer models.",
                    "url": "https://meetinglibrary.asco.org/record/157544/abstract"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 5885,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, G1T38 did not inhibit growth of AR and RB1-negative prostate cancer cell lines in culture (AACR, Cancer Res: April 2016; Volume 57, Abstract #2820).",
            "molecularProfile": {
                "id": 21979,
                "profileName": "AR neg RB1 neg"
            },
            "therapy": {
                "id": 3970,
                "therapyName": "G1T38",
                "synonyms": null
            },
            "indication": {
                "id": 10283,
                "name": "prostate cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 5183,
                    "pubMedId": null,
                    "title": "Effects of a CDK 4/6 inhibitor, G1T38, in androgen receptor sensitive and resistant models of castrate resistant prostate cancer",
                    "url": "http://www.abstractsonline.com/Plan/ViewAbstract.aspx?mID=4017&sKey=12eab58f-9b3f-418d-ad0c-e55a553a95b9&cKey=90cf56d3-fe9d-4b4d-8477-6867a79402af&mKey=1d10d749-4b6a-4ab3-bcd4-f80fb1922267"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 5886,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, G1T38 treatment resulted in growth inhibition in AR-negative, RB1-positive prostate cancer cell lines in culture (AACR, Cancer Res: April 2016; Volume 57, Abstract #2820).",
            "molecularProfile": {
                "id": 21980,
                "profileName": "AR neg RB1 pos"
            },
            "therapy": {
                "id": 3970,
                "therapyName": "G1T38",
                "synonyms": null
            },
            "indication": {
                "id": 10283,
                "name": "prostate cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 5183,
                    "pubMedId": null,
                    "title": "Effects of a CDK 4/6 inhibitor, G1T38, in androgen receptor sensitive and resistant models of castrate resistant prostate cancer",
                    "url": "http://www.abstractsonline.com/Plan/ViewAbstract.aspx?mID=4017&sKey=12eab58f-9b3f-418d-ad0c-e55a553a95b9&cKey=90cf56d3-fe9d-4b4d-8477-6867a79402af&mKey=1d10d749-4b6a-4ab3-bcd4-f80fb1922267"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 20779,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, overexpressing TMPRSS2-ERG in AR-negative prostate cancer cells did not confer sensitivity to Lynparza (olaparib) in cell culture (PMID: 29465803).",
            "molecularProfile": {
                "id": 35332,
                "profileName": "TMPRSS2 - ERG AR neg"
            },
            "therapy": {
                "id": 837,
                "therapyName": "Olaparib",
                "synonyms": null
            },
            "indication": {
                "id": 10283,
                "name": "prostate cancer",
                "source": "DOID"
            },
            "responseType": "no benefit",
            "references": [
                {
                    "id": 18040,
                    "pubMedId": 29465803,
                    "title": "Olaparib is effective in combination with, and as maintenance therapy after, first-line endocrine therapy in prostate cancer cells.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29465803"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        }
    ],
    "molecularProfiles": [
        {
            "id": 18586,
            "profileName": "AR negative",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 21979,
            "profileName": "AR neg RB1 neg",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 21980,
            "profileName": "AR neg RB1 pos",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 35332,
            "profileName": "TMPRSS2 - ERG AR neg",
            "profileTreatmentApproaches": [
                
            ]
        }
    ],
    "allTranscriptCoordinates": [
        
    ]
}